Global Growth Companies With High Insider Ownership And 62 Percent Earnings Growth

In This Article:

As global markets navigate a landscape marked by easing inflation in the U.S. and ongoing trade uncertainties, investors are increasingly focused on identifying robust opportunities amid the volatility. In such an environment, growth companies with high insider ownership can present compelling prospects, as they often indicate strong confidence from those closest to the business and can be well-positioned to capitalize on favorable economic shifts.

Top 10 Growth Companies With High Insider Ownership Globally

Name

Insider Ownership

Earnings Growth

Vow (OB:VOW)

13.1%

120.9%

Pharma Mar (BME:PHM)

11.8%

40.8%

Laopu Gold (SEHK:6181)

36.4%

45.7%

CD Projekt (WSE:CDR)

29.7%

39.1%

Elliptic Laboratories (OB:ELABS)

22.6%

88.2%

Nordic Halibut (OB:NOHAL)

29.8%

56.3%

HANA Micron (KOSDAQ:A067310)

18.3%

125.9%

Fulin Precision (SZSE:300432)

13.6%

78.6%

Ascentage Pharma Group International (SEHK:6855)

17.9%

60.9%

Synspective (TSE:290A)

13.2%

37.4%

Click here to see the full list of 886 stocks from our Fast Growing Global Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Newborn Town

Simply Wall St Growth Rating: ★★★★★☆

Overview: Newborn Town Inc. is an investment holding company that operates in the global social networking sector with a market cap of HK$9.16 billion.

Operations: The company's revenue primarily comes from its Social Networking Business, generating CN¥3.80 billion, with an additional CN¥406.28 million from its Innovative Business segment.

Insider Ownership: 22.1%

Earnings Growth Forecast: 22.4% p.a.

Newborn Town's earnings are forecast to grow at 22.4% annually, outpacing the Hong Kong market. Despite recent shareholder dilution, the company trades below its estimated fair value and offers good relative value compared to peers. Recent guidance indicates a significant revenue increase driven by AI-powered social apps and acquisitions, though net profit growth is more modest due to prior one-off gains. Leadership changes bring new expertise in capital markets and technology investment.

SEHK:9911 Earnings and Revenue Growth as at Mar 2025
SEHK:9911 Earnings and Revenue Growth as at Mar 2025

Jiangsu Sinopep-Allsino Biopharmaceutical

Simply Wall St Growth Rating: ★★★★★★

Overview: Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. is a biomedical company involved in the R&D, production, sale, and technical service of peptides and small molecule drugs in China, with a market cap of CN¥12.96 billion.